Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies.

ABSTRACT:

Background/objectives

Chemotherapy remains standard for many cancers, but challenges remain in evaluating clinical response to therapy. Epigenomic circulating tumor DNA (ctDNA) quantification is an emerging molecular approach to tumor response assessment. Here, we examine a tissue-free, methylation-based assay to demonstrate how changes in circulating tumor fraction (TF) associate with outcomes in a real-world advanced, pan-cancer cohort treated with chemotherapy.

Methods

This retrospective study evaluated patients with advanced solid tumors treated with chemotherapy and serial ctDNA testing, both pre- and post-therapy initiation. Serial samples were analyzed with an analytically validated next-generation sequencing (NGS) methylation-based ctDNA assay. The primary outcome me

SUBMITTER: Rolfo CD 

PROVIDER: S-EPMC12630033 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature